Clinical trials: Rituximab, completed
Waldenstrom's Macroglobulinemia
Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia
Carfilzomib is a drug that has shown anti-tumor activity by inhibiting the proteasome within the cell, which is responsible for degrading or breaking down a wide variety of proteins. Carfilzomib has not been approved by the FDA.
- Trial name
- CaRD (NCT01470196)
- Testing
- Dexamethasone, Carfilzomib, Rituximab
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Dana-Farber Cancer Institute
Large B-Cell Diffuse Lymphoma
Oral Azacitidine Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma
The purpose of this study is to determine the safety and tolerability of adding oral azacitidine to the chemotherapy combination R-ICE. This study will also look at whether or not disease outcomes improve with the combination.
- Trial name
- NCT03450343
- Testing
- Oral azacitidine, R-ICE
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Medical University of South Carolina
Non-Hodgkin's Lymphoma, Diffuse Large B-cell Lymphoma
Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL
This was a Phase 1/2 study performed at two clinical centers in the US and UK. It was a single arm, open label study evaluating VSLI plus rituximab in adults with aggressive relapsed or refractory non-Hodgkin's lymphoma.
- Conditions
- Non-Hodgkin's Lymphoma, Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma
- Trial name
- NCT01851551
- Testing
- Vincristine Sulfate Liposome Injection plus rituximab
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 22 people
- Sponsor
- Acrotech Biopharma Inc.
Retroperitoneal Fibrosis, Autoimmune Pancreatitis
Rituximab in IgG4-RD: A Phase 1-2 Trial
The primary objective of this study is to evaluate the safety and effectiveness of rituximab in IgG4-RD.
- Conditions
- Retroperitoneal Fibrosis, Autoimmune Pancreatitis, Sialadenitis, Pseudotumor
- Trial name
- NCT01584388
- Testing
- Rituximab
- Volunteers
- 30 people
- Sponsor
- Massachusetts General Hospital
Pulmonary Alveolar Proteinosis, Primary Disease
Prospective Trial of Rituximab for Primary Pulmonary Alveolar Proteinosis
The purpose of this study is to determine whether the use of rituximab is effective in treating pulmonary alveolar proteinosis by leading to an improvement in lung function and disease status.
- Trial name
- PAP (NCT00552461)
- Testing
- rituximab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- East Carolina University
Lymphoma
Avastin Plus Rituximab for Patients With B-Cell Non-Hodgkin's Lymphoma
Phase II Study of Avastin Plus Rituximab for Patients with Relapsed and Chemotherapy - or Rituxan Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma.
- Trial name
- NCT00081861
- Testing
- Avastin, Rituximab
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Lymphoma, Large B-Cell, Diffuse
90Y-ibritumomab Tiuxetan Consolidation After 6th R-CHOP Chemotherapy in Patients With Bulky Diffuse Large B Cell Lymphoma
This phase II study is aimed at the clinical efficacy and toxicity of 6th R-CHOP chemotherapy followed by ibritumomab tiuxetan (Zevalin) consolidation in patients with limited-stage, bulky diffuse large B cell lymphoma (DLBCL).
- Trial name
- NCT01157988
- Testing
- ibritumomab tiuxetan (Zevalin)
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Chonnam National University Hospital
Renal Transplantation
A Pilot Study of Campath-1H Induction Therapy Combined With CellCept® Therapy to Allow for a Calcineurin Inhibitor Free Regimen After Renal Transplantation
The hypothesis of this study is that lymphocyte depletion by Campath-1H and rituximab will obviate the need for long-term calcineurin inhibitors in renal transplantation.
- Trial name
- NCT00214266
- Testing
- Campath 1H®, Rituximab, mycophenolate mofetil
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Wisconsin, Madison
Diffuse Large B Cell Lymphoma
FDG-PET-Stratified R-DICEP and R-Beam/ASCT For Diffuse Large B-Cell Lymphoma
The purpose of this study is to evaluate: 1. whether an imaging test called a PET (Positron emission tomography) scan performed after two cycles of standard chemotherapy is able to identify patients who have a high cure rate…
- Trial name
- PET-Chop (NCT00530179)
- Testing
- Autologous Blood Stem Transplantation, R-CHOP
- Where
- 3 sites in Canada
- Volunteers
- 69 people
- Sponsor
- AHS Cancer Control Alberta
Non-Hodgkins Lymphoma
Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma
The purposes of this trial are to decrease toxicity and improve treatment effectiveness elderly patients. With a short course of chemotherapy with cyclophosphamide, mitoxantrone, vincristine, and prednisone with concurrent…
- Trial name
- NCT00193479
- Testing
- Cyclophosphamide, Mitoxantrone, Vincristine
- Where
- 2 sites in United States
- Volunteers
- 51 people
- Sponsor
- SCRI Development Innovations, LLC
Thrombotic Thrombocytopenic Purpura (TTP)
The Use of Rituximab in Acute Thrombotic Thrombocytopenic Purpura (TTP)
TTP is a rare and serious blood disorder, characterized by the formation of small clots (micro thrombi) within the circulation and can be fatal.
- Trial name
- NCT00937131
- Testing
- Rituximab
- Where
- 3 sites in United Kingdom
- Volunteers
- 40 people
- Sponsor
- University College, London
Lymphoma
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Previously Untreated HIV-Associated Non-Hodgkin's Lymphoma
Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without monoclonal antibody therapy in treating patients who have previously untreated HIV-associated non-Hodgkin's lymphoma.
- Trial name
- NCT00003595
- Testing
- filgrastim, rituximab, CHOP regimen
- Where
- 13 sites in United States
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma, Hodgkin Disease
Azacitidine With Rituximab, Vincristine, and Cyclophosphamide in Refractory Lymphoma
This is a phase I, prospective, open label, dose escalation study of azacitidine in combination with rituximab, vincristine, and cyclophosphamide for the treatment of refractory lymphoma.
- Conditions
- Lymphoma, Hodgkin Disease, Lymphoma, Non-Hodgkin
- Trial name
- NCT00901069
- Testing
- Azacitidine with rituximab, vincristine, and cyclophosphamide
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Shams Shakil
Mantle Cell Lymphoma
Phase 2 Hyper-CVAD/Rituximab for Untreated Mantle Cell Lymphoma
rituximab and modified (hyperCVAD) administered every 28 days for 4-6 cycles followed by rituximab maintenance therapy consisting of four weekly doses every six months for two years
- Trial name
- NCT00581854
- Testing
- modified Hyper-CVAD
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Wisconsin, Madison
Lymphoma
Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma
RATIONALE: Drugs used in chemotherapy, such as doxorubicin, vincristine, and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00690560
- Testing
- rituximab, cyclophosphamide, doxorubicin hydrochloride
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Centre Antoine Lacassagne
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma
Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant
This phase I trial studies the side effects and best dose of olaparib when given together with high-dose chemotherapy in treating patients with lymphomas that have come back or does not treatment and are undergoing stem cell…
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Hodgkin Lymphoma
- Trial name
- NCT03259503
- Testing
- Busulfan, Gemcitabine, Melphalan
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- M.D. Anderson Cancer Center
Large B-cell Diffuse Lymphoma of Testis
Safety and Feasibility Study of Combination of State of Art Chemoimmunotherapy, Intensive Central Nervous System Prophylaxis and Scrotal Irradiation to Treat Primary Diffuse Large B-cell Lymphoma of Testis
This trial is a phase II non-comparative study aimed to determine the feasibility and toxicity of the R-CHOP regimen in combination with intrathecal liposomal cytarabine and systemic intermediate-dose methotrexate followed by…
- Trial name
- IELSG30 (NCT00945724)
- Testing
- Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone, liposomal cytarabine, methotrexate
- Where
- 22 sites in Italy, Switzerland
- Volunteers
- 54 people
- Sponsor
- International Extranodal Lymphoma Study Group (IELSG)
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Etanercept and Rituximab in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
This is a phase I/II study of the combination of etanercept and rituximab in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
- Trial name
- NCT00201682
- Testing
- Etanercept, Rituximab
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- John Byrd
Lymphoma, Mantle-Cell
Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma
Study of Yttrium-ibritumomab (Zevalin) For the treatment of Patients with Relapsed \& Refractory Mantle Cell Lymphoma
- Trial name
- NCT00038623
- Testing
- Yttrium-ibritumomab (Zevalin), Rituximab
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Renal Transplant
IVIG/Rituximab vs Rituximab in Kidney Transplant With de Novo Donor-specific Antibodies
The objective of this study was to compare two strategies of de novo donor specific antibodies (DSA) and antibody-mediated rejection (AMR) prevention in renal transplant recipients: high dose intravenous immunoglobulin…
- Trial name
- NCT04033276
- Testing
- Rituximab, intravenous immune globulin
- Where
- 2 sites in South Korea
- Volunteers
- 50 people
- Sponsor
- Seoul National University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.